Google
VYNE — VYNE THERAPEUTICS INC (Healthcare >> Biotechnology)
VYNE FAQ
What is VYNE's ROE?
VYNE THERAPEUTICS INC reports a Return on Equity (ROE) of -87.09%.
What is VYNE's dividend yield?
VYNE THERAPEUTICS INC offers a dividend yield of 0.00%.
What is VYNE's Deepscope Quality Score?
Deepscope rates VYNE's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy VYNE?
Deepscope's AI Timing Score for VYNE is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does VYNE belong to?
VYNE THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.67
Price
0.01
(1.39%)
Day Change
|
|
|---|
VYNE, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.67 |
| PBV / Sector |
0.92 / 4.58
GREAT
|
| Earning Per Share | -0.63 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
0.10 M
GREAT
|
| Average 1W Daily Value |
0.07 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-05 09:12:34 |
| Symbol | VYNE |
| Name | VYNE THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 33.35 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 22.55 / 8,655.90 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: P.O. BOX 125, Stewartsville, NJ, United States, 08886
Phone: 800 775 7936
Website: https://vynetherapeutics.com
Sector: Healthcare >> Biotechnology
Description: VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
